Arcutis Biotherapeutics Stock Current Liabilities
| ARQT Stock | USD 12.69 0.44 3.59% |
Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.
Total Current Liabilities is likely to drop to about 23.4 M in 2024. Non Current Liabilities Total is likely to drop to about 115.9 M in 2024. Arcutis | Current Liabilities |
Arcutis Biotherapeutics Company Current Liabilities Analysis
Arcutis Biotherapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Arcutis Biotherapeutics Current Liabilities | 4.42 M |
Most of Arcutis Biotherapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcutis Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcutis Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcutis Biotherapeutics is extremely important. It helps to project a fair market value of Arcutis Stock properly, considering its historical fundamentals such as Current Liabilities. Since Arcutis Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcutis Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcutis Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Arcutis Current Liabilities Historical Pattern
Today, most investors in Arcutis Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcutis Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arcutis Biotherapeutics current liabilities as a starting point in their analysis.
Arcutis Biotherapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Arcutis Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Arcutis Biotherapeutics has a Current Liabilities of 4.42 M. This is 99.75% lower than that of the Biotechnology sector and 99.19% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.94% higher than that of the company.
Arcutis Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcutis Biotherapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics of similar companies.Arcutis Biotherapeutics is currently under evaluation in current liabilities category among its peers.
Arcutis Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 830.3M | 1.0B | 1.0B | 223.9M | 257.4M | 244.6M | |
| Enterprise Value | 767.3M | 943.2M | 1.0B | 341.4M | 392.6M | 373.0M |
Arcutis Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcutis Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 2.14 % | ||||
| Shares Owned By Institutions | 97.86 % | ||||
| Number Of Shares Shorted | 23.53 M | ||||
| Price To Book | 9.15 X | ||||
| Price To Sales | 10.78 X | ||||
| Revenue | 59.61 M | ||||
| Gross Profit | 2.93 M | ||||
| EBITDA | (227.43 M) | ||||
| Net Income | (262.14 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 205.92 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (247.06 M) | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 296 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.49 B | ||||
| Total Asset | 341.37 M | ||||
| Retained Earnings | (981.9 M) | ||||
| Working Capital | 283.76 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
| Net Asset | 341.37 M |
About Arcutis Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.